FDA-Initiated OTC Switches Could Be Based On Foreign Data – McClellan
This article was originally published in The Tan Sheet
Executive Summary
FDA may rely on a drug's foreign OTC marketing experience to determine whether an Rx product should be switched OTC in the U.S. without sponsor consent, Commissioner Mark McClellan, MD/PhD, said at a Manhattan Institute roundtable discussion for buyside analysts May 16
You may also be interested in...
Behind-The-Counter Drug Class “On The Table” At CHPA
The Consumer Healthcare Products Association appears to have softened its steadfast opposition to a possible behind-the-counter third class of drugs
OTC Labeling Adopted By FDA In Forced Switch Would Violate Regs Comments Say
FDA could not adopt a drug's approved OTC label from another country as acceptable U.S. OTC labeling without violating its own regulations, according to the American Association of Physicians & Surgeons and Competitive Enterprise Institute
OTC Labeling Adopted By FDA In Forced Switch Would Violate Regs Comments Say
FDA could not adopt a drug's approved OTC label from another country as acceptable U.S. OTC labeling without violating its own regulations, according to the American Association of Physicians & Surgeons and Competitive Enterprise Institute